Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for EGFR-mutated non-small-cell lung cancer, drawn from the whole corpus: 163 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No head-to-head trial compares the three first-line strategies, and the added toxicity of the combinations falls on every patient for a benefit concentrated in some.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Most resistance to osimertinib has no identifiable mechanism and no targeted option.
Background: Drug resistance (primary and acquired), EGFR C797S, Histologic transformation, MET amplification (bypass resistance). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Whether adjuvant osimertinib cures more patients or delays recurrence beyond the three years of treatment is still being followed.
Nothing recorded yet.
Background: Neoadjuvant / adjuvant / perioperative. Also on OnCo: Treatment journeys · Survivorship planner.
Checkpoint inhibitors add little and increase pneumonitis when combined with EGFR inhibitors.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 23 changes by month →When this page itself was last checked or edited.
PFS HR 0.
A milestone in how this cancer is treated.
PFS HR 0.
A milestone in how this cancer is treated.
PFS HR 0.